Suven Life Sciences will be a tonic in portfolio
Suven life sciences at Rs 170, promises to defy gravity as it has reached the bottom.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。